Revolution Medicines (RVMD) CCO Anthony Mancini Exercises Options, Sells Shares

What Happened

• Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines (RVMD), exercised stock options for 9,363 shares at a $33.62 strike (cost ~$314,784) and sold a total of 15,448 shares in open-market transactions on September 10, 2026, generating approximately $3,153,806 in proceeds. The filing also reports a derivative conversion/disposition of 9,363 shares (reported at $0).
• The sales were executed in multiple trades at weighted-average prices shown below and were made under a pre-established 10b5-1 trading plan.

Key Details

• Transaction date: 2026-09-10; Form 4 filed 2026-09-14 (timely).
• Exercise: 9,363 shares exercised at $33.62 = $314,784 (reported as code M).
• Sales (open market):
  • 6,019 shares @ weighted avg $203.28 (range $202.64–$203.63) = $1,223,569
  • 5,530 shares @ weighted avg $204.14 (range $203.64–$204.63) = $1,128,870
  • 2,420 shares @ weighted avg $205.05 (range $204.64–$205.55) = $496,224
  • 1,179 shares @ weighted avg $206.10 (range $205.85–$206.70) = $242,991
  • 300 shares @ weighted avg $207.17 (range $207.12–$207.28) = $62,152
  • Total proceeds from sales ≈ $3,153,806.
• Reporting notes: Transactions executed under a 10b5-1 plan adopted June 11, 2026 (Footnote F1). Several sales executed in multiple trades—weighted-average prices reported; detailed price breakdowns available upon request (Footnotes F2–F6).
• Shares owned after the reported transactions are not specified in the excerpt; the filing notes inclusion of 43,700 restricted stock units (Footnote F7).
• Transaction codes: M = option exercise/conversion; S = sale.

Context

• This was an option exercise followed by open-market sales (shares acquired via exercise were sold as part of the reported transactions). The use of a 10b5-1 plan indicates the sales were pre-planned under an approved trading arrangement rather than ad-hoc trades.
• These are routine insider transactions and do not, by themselves, indicate the insider’s view on the company’s prospects.